TH9619 is a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2, highly overexpressed and cancer-specific enzymes within the one-carbon metabolic pathway. TH9619 kills cancer cells via a dual mechanism of action (1) inhibition of MTHFD1 traps folate leading to thymidine depletion (2) inhibition of nuclear MTHFD2 disrupts DNA damages response repair pathways. With its unique characteristics, TH9619 kills tumor cells, while sparing healthy tissues. Based on the strong pre-clinical data, the company is targeting difficult to treat advanced refractory solid tumors.
One-carbon Therapeutics AB has secured seed funding and is now focused on completing enrolment of phase 1a (dose finding) of their ODIN Phase 1/2 study (NCT07151040; EudraCT 2024-519639-40-00).
One-carbon Therapeutics
One-carbon Therapeutics AB is a clinical-stage biotechnology company headquartered in Sweden, pioneering novel anti-cancer therapies. Their most advanced candidate - TH9619 - has started clinical development in 2025.
